Roche has decided to stop developing satralizumab for bone health in Duchenne muscular dystrophy, the company announced.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...
New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history -- Data expand ...
Sarepta has come under scrutiny over Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). With a one-time ...
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ), a biopharmaceutical leader in rare diseases and subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today ...
Breaking stock news is now free. Create your account to stay informed—and explore the insights behind every move. Dyne Therapeutics, Inc. ( DYN) TD Cowen 46th Annual Health Care Conference March 4, ...
SBI Deputy Managing Director Nitin Chugh, who led the bank's digital banking and transformation initiatives including YONO ...
Sen. Roger Wicker urges states to add Duchenne muscular dystrophy to newborn screening, after federal health officials back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results